StreetInsider.com News Articles

Form 4 ABBOTT LABORATORIES For: Sep 01 Filed by: MCCOY JOHN A. JR.

Thu, 03 Sep 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260903/27026280.html

Form 4 ABBOTT LABORATORIES For: Sep 01 Filed by: Boudreau Philip P

Thu, 03 Sep 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260903/27026248.html

Form 144 ABBOTT LABORATORIES Filed by: MCCOY JOHN A. JR.

Wed, 02 Sep 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260902/27020170.html

Form 144 ABBOTT LABORATORIES Filed by: Ford Robert B

Mon, 31 Aug 2026 12:53:00 -0400

si-local-file:///var/storage/secattach/20260831/27004158.html

Abbott launches whole milk ready-to-feed infant formula in the U.S.

Mon, 31 Aug 2026 08:01:18 -0400

Abbott (NYSE: ABT) has launched Similac 360 Total Care Made With Whole Milk, which the company claims is the first commercially sterile, ready-to-feed liquid infant formula made with whole milk available in the United States.

The product is available in 8 fl oz and 32 fl oz sizes and is priced at a per-feeding cost similar to Abbott's existing Similac 360 Total Care powdered infant formulas. Liquid infant formulas typically carry a higher price than powdered alternatives.

The formula contains whole milk and a blend of five human milk oligosaccharides, which are prebiotics. Abbott states the product does not contain corn syrup,

Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

Mon, 31 Aug 2026 08:00:00 -0400

New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milk
Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula
Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailers

ABBOTT PARK,

Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

Mon, 31 Aug 2026 08:00:00 -0400

New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support baby's natural defenses—making it Similac's closest formula to breast milk
Abbott's liquid-only launch reflects growing parent interest in infant formulas made with whole milk while offering the convenience and reassurance that comes with commercially sterile, ready-to-feed formula
Product is available at prices similar to the per-feeding cost of powdered Similac 360 Total Care and is available online and at major U.S. retailers

ABBOTT PARK,

Form 4 ABBOTT LABORATORIES For: Aug 25 Filed by: Ford Robert B

Thu, 27 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26991147.html

Form 4 ABBOTT LABORATORIES For: Aug 25 Filed by: Ford Robert B

Thu, 27 Aug 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26991147.html

Abbott wins CE Mark for Amulet 360 heart device in Europe

Thu, 27 Aug 2026 09:00:59 -0400

Abbott (NYSE: ABT) has received CE Mark approval for its Amulet 360 Left Atrial Appendage (LAA) Occluder, a device designed to reduce stroke risk in patients with non-valvular atrial fibrillation (AFib), according to a company statement.

The device seals the left atrial appendage, a small pouch in the heart's upper left chamber where blood clots commonly form in AFib patients. It is intended as an alternative for patients who cannot tolerate long-term blood-thinning medication.

Following approval, the first European procedures using Amulet 360 were performed at three sites: the Cardiovascular Clinic Bethanien in Frankfurt, Germany; the University Heart Center in Lubeck, Germany;

Abbott wins CE Mark for Amulet 360 heart device in Europe

Thu, 27 Aug 2026 09:00:59 -0400

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Thu, 27 Aug 2026 09:00:00 -0400

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication
Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke
Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness

ABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Thu, 27 Aug 2026 09:00:00 -0400

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication
Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke
Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Thu, 27 Aug 2026 09:00:00 -0400

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication
Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke
Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness

Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

Thu, 27 Aug 2026 09:00:00 -0400

Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication
Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke
Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness

Form 144 ABBOTT LABORATORIES Filed by: Ford Robert B

Tue, 25 Aug 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26975908.html

Form 144 ABBOTT LABORATORIES Filed by: Ford Robert B

Tue, 25 Aug 2026 18:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26975908.html

Abbott wins FDA clearance for dual glucose-ketone diabetes sensor

Tue, 25 Aug 2026 14:50:42 -0400

Abbott (NYSE: ABT) said it received U.S. Food and Drug Administration authorization for its Libre Duo 10 Day system, which the company claims is the first device to continuously monitor both glucose and ketone levels in people with diabetes.

The device received De Novo authorization after securing FDA breakthrough device designation. Abbott said it is the first system to meet both the FDA's integrated continuous glucose monitoring standard and a newly established integrated continuous glucose and ketone monitoring standard for the United States. The company plans to launch the product in the U.S. later this year. Abbott also received CE Mark

Abbott wins FDA clearance for dual glucose-ketone diabetes sensor

Tue, 25 Aug 2026 14:50:42 -0400

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes